AIM: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficiency; therefore, we determined the CYP2D6 allele distribution in eight Amerindian groups from northwestern Mexico and compared them with the frequencies in Mexican Mestizos. MATERIALS & METHODS: A total of 508 Amerindians were studied. Genotyping of CYP2D6*5 and multiplication alleles was performed by long-range PCR, while CYP2D6*2, *3, *4, *6, *10, *17, *29, *35, *41 and copy number were evaluated by real-time PCR. RESULTS: The most frequent alleles were CYP2D6*2 (0.05-0.28), CYP2D6*4 (0.003-0.21) and multiplications (0.043-0.107). CYP2D6*5, *6, * 10 and *41 were not observed in the majority of Amerindians, and CYP2D6*3, *17, *35 and *29 were not detected. The poor metabolizer genotype ( *4/*5) was lower (0.2%) in Amerindians than in Mestizos (5%); conversely, the ultrarapid metabolizer genotype was higher (12.6%) in indigenous groups than in Mestizos (7%). CONCLUSION: Our data show a lower frequency of CYP2D6 inactive alleles and a higher frequency of duplication/multiplication of CYP2D6 active alleles in indigenous populations that in Mestizos. Original submitted 14 August 2013; Revision submitted 7 October 2013.
AIM: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficiency; therefore, we determined the CYP2D6 allele distribution in eight Amerindian groups from northwestern Mexico and compared them with the frequencies in Mexican Mestizos. MATERIALS & METHODS: A total of 508 Amerindians were studied. Genotyping of CYP2D6*5 and multiplication alleles was performed by long-range PCR, while CYP2D6*2, *3, *4, *6, *10, *17, *29, *35, *41 and copy number were evaluated by real-time PCR. RESULTS: The most frequent alleles were CYP2D6*2 (0.05-0.28), CYP2D6*4 (0.003-0.21) and multiplications (0.043-0.107). CYP2D6*5, *6, * 10 and *41 were not observed in the majority of Amerindians, and CYP2D6*3, *17, *35 and *29 were not detected. The poor metabolizer genotype ( *4/*5) was lower (0.2%) in Amerindians than in Mestizos (5%); conversely, the ultrarapid metabolizer genotype was higher (12.6%) in indigenous groups than in Mestizos (7%). CONCLUSION: Our data show a lower frequency of CYP2D6 inactive alleles and a higher frequency of duplication/multiplication of CYP2D6 active alleles in indigenous populations that in Mestizos. Original submitted 14 August 2013; Revision submitted 7 October 2013.
Authors: Vanessa Gonzalez-Covarrubias; José Jaime Martínez-Magaña; Regina Coronado-Sosa; Beatriz Villegas-Torres; Alma D Genis-Mendoza; Pablo Canales-Herrerias; Humberto Nicolini; Xavier Soberón Journal: Pharm Res Date: 2016-07-07 Impact factor: 4.200
Authors: M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena Journal: Pharmacogenomics J Date: 2016-06-07 Impact factor: 3.550
Authors: Deise C Friedrich; Júlia P Genro; Vinicius A Sortica; Guilherme Suarez-Kurtz; Maria Elizabete de Moraes; Sergio D J Pena; Andrea K Ribeiro dos Santos; Marco A Romano-Silva; Mara H Hutz Journal: PLoS One Date: 2014-10-20 Impact factor: 3.240
Authors: Luciana P C Leitão; Tatiane P Souza; Juliana C G Rodrigues; Marianne R Fernandes; Sidney Santos; Ney P C Santos Journal: Genes (Basel) Date: 2020-02-28 Impact factor: 4.096
Authors: Marianne Rodrigues Fernandes; Juliana Carla Gomes Rodrigues; Olalla Maroñas; Ana Latorre-Pellicer; Raquel Cruz; João Farias Guerreiro; Rommel Mario Rodriguez Burbano; Paulo Pimentel de Assumpção; Andrea Ribeiro-Dos-Santos; Sidney Emanuel Batista Dos Santos; Angel Carracedo; Ney Pereira Carneiro Dos Santos Journal: Pharmgenomics Pers Med Date: 2021-01-22
Authors: Fernando de Andrés; Catalina Altamirano-Tinoco; Ronald Ramírez-Roa; Carlos F Montes-Mondragón; Pedro Dorado; Eva M Peñas-Lledó; Adrián LLerena Journal: Pharmacogenomics J Date: 2020-10-06 Impact factor: 3.550
Authors: Lindsay M Henderson; Katrina G Claw; Erica L Woodahl; Renee F Robinson; Bert B Boyer; Wylie Burke; Kenneth E Thummel Journal: J Pers Med Date: 2018-02-01